Monoclonal antibodies targeting CGRP or its receptor represent the first migraine-specific preventive treatments, developed from 35 years of translational research linking CGRP to migraine pathophysiology.
35 years to clinical successCGRP antibodies represent 35 years of translational research from neuropeptide discovery to migraine-specific prevention
What the researchers found
CGRP/receptor-targeting monoclonal antibodies represent a paradigm shift from repurposed treatments to migraine-specific prevention, with strong clinical trial evidence supporting their efficacy and favorable safety profiles.
Why it matters
Migraine affects over 1 billion people worldwide and was previously treated with drugs designed for other conditions. These antibodies are the first treatments designed specifically for migraine biology.
The numbers in context
50% responder rate advantage: 21.4% episodic, 17.4% chronic; NNT 4-5 episodic; 4 monoclonal antibodies reviewed
How the study worked
Review of translational research history, clinical trial data, and clinical experience with CGRP-blocking monoclonal antibodies and gepants for migraine prevention.
Who was studied
Patients with episodic and chronic migraine across multiple RCTs
What this study cannot tell us
Review format. Long-term safety data still accumulating. Cost remains a barrier for many patients. Not all migraine patients respond to anti-CGRP therapy. Head-to-head comparisons between different antibodies are limited.
How to read the evidence
Strong — review of large-scale clinical trial programs for multiple approved antibodies with consistent positive results.
When this study was published
Published in 2020; since then, additional CGRP-targeting therapies including oral gepants have expanded treatment options.
The bigger picture
The CGRP antibody story represents one of the most successful examples of bench-to-bedside translational medicine, where basic neuropeptide research led directly to a new class of targeted therapeutics.
Questions still open
- What characterizes patients who respond well versus poorly to anti-CGRP antibodies?
- Will oral CGRP receptor antagonists (gepants) reduce the need for injectable antibodies?
- Are there long-term consequences of sustained CGRP blockade?
Common questions
How are CGRP antibodies different from triptans?
What makes these the first migraine-specific treatments?
Read the original research
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Revue neurologique, 176(10), 788-803
Citation
Schoenen, J; Manise, M; Nonis, R; Gérard, P; Timmermans, G. (2020). Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.. Revue neurologique, 176(10), 788-803. https://doi.org/10.1016/j.neurol.2020.04.027